KE3728A - Food process - Google Patents

Food process

Info

Publication number
KE3728A
KE3728A KE3728A KE372887A KE3728A KE 3728 A KE3728 A KE 3728A KE 3728 A KE3728 A KE 3728A KE 372887 A KE372887 A KE 372887A KE 3728 A KE3728 A KE 3728A
Authority
KE
Kenya
Prior art keywords
citrate
food process
phosphate
whey proteins
solution
Prior art date
Application number
KE3728A
Other languages
English (en)
Inventor
De Rham Olivier
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4237743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KE3728(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of KE3728A publication Critical patent/KE3728A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1425—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of whey, e.g. treatment of the UF permeate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1427—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by dialysis, reverse osmosis or hyperfiltration, e.g. for concentrating or desalting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/146—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by ion-exchange
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/04—Animal proteins
    • A23J3/08—Dairy proteins

Landscapes

  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Water Supply & Treatment (AREA)
  • Nutrition Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dairy Products (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Braking Arrangements (AREA)
KE3728A 1983-05-13 1987-05-13 Food process KE3728A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH261583 1983-05-13

Publications (1)

Publication Number Publication Date
KE3728A true KE3728A (en) 1987-06-05

Family

ID=4237743

Family Applications (1)

Application Number Title Priority Date Filing Date
KE3728A KE3728A (en) 1983-05-13 1987-05-13 Food process

Country Status (17)

Country Link
US (1) US4748034A (ja)
EP (1) EP0126290B2 (ja)
JP (1) JPS59216544A (ja)
AT (1) ATE24658T1 (ja)
AU (1) AU564405B2 (ja)
CA (1) CA1200416A (ja)
DE (1) DE3461886D1 (ja)
DK (1) DK235584D0 (ja)
ES (1) ES532469A0 (ja)
GB (1) GB2139630B (ja)
HK (1) HK73787A (ja)
KE (1) KE3728A (ja)
MX (1) MX167579B (ja)
MY (1) MY100729A (ja)
NZ (1) NZ208086A (ja)
SG (1) SG35687G (ja)
ZA (1) ZA843213B (ja)

Families Citing this family (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH672230A5 (ja) * 1987-10-15 1989-11-15 Nestle Sa
FR2634104B1 (fr) * 1988-07-18 1991-10-18 Union Coop Agricole Hydrolysat partiel de proteines de lactoserum, procede enzymatique de preparation de cet hydrolysat, et aliment lacte dietetique hypoallergenique le contenant
DE4002204A1 (de) * 1990-01-26 1991-08-01 Westfalen Milchwerke Diaetetisches nahrungsmittel fuer patienten mit niereninsuffizienz
NL9001692A (nl) * 1990-04-26 1991-11-18 Cooeperatieve Melkproductenbed Werkwijze voor de bereiding van een olie-in-water emulsie.
JP3065116B2 (ja) * 1991-02-25 2000-07-12 株式会社第一化成 透明な乳清タンパク質加工品の製造法
JP3059595B2 (ja) * 1992-11-20 2000-07-04 森永乳業株式会社 沈澱を生じない乳清蛋白質分解物の製造法
US5350590A (en) * 1992-12-15 1994-09-27 Beatreme Foods Inc. Protein fat replacer and method of manufacture thereof
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
DK1493439T3 (da) 1997-04-02 2012-01-30 Brigham & Womens Hospital Middel til fastlæggelse af en persons risikoprofil for aterosklerotisk sygdom
EP1096952B1 (en) 1998-07-15 2008-05-21 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6106874A (en) * 1998-11-18 2000-08-22 Abbott Laboratories Calcium fortified juice-based nutritional supplement and process of making
WO2001060183A2 (en) * 2000-02-17 2001-08-23 Welch Foods, Inc. Calcium-fortified, grape-based products and methods for making them
CA2402160C (en) 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
AU2001253597A1 (en) * 2000-04-12 2001-10-30 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
AU2001277230A1 (en) * 2000-08-01 2002-02-13 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution andparticles made thereby
RU2174756C1 (ru) * 2000-09-18 2001-10-20 Борисов Александр Борисович Пищевой продукт
DE10062056A1 (de) * 2000-12-15 2002-07-04 Henkel Ecolab Gmbh & Co Ohg Verfahren zur Reinigung von Ionenaustauscher-Kunststoffharzen
EP1446104B2 (en) * 2001-11-01 2011-08-03 Novartis AG Spray drying methods
ATE369045T1 (de) * 2001-11-26 2007-08-15 Nestec Sa Lagerstabiles nahrungsmittelprodukt enthaltend molkenprotein, verfahren zu seiner herstellung und verwendung
US20030165574A1 (en) * 2002-03-01 2003-09-04 Ward Loren Spencer Compositions and methods for treatment of body weight conditions
EP2284535A1 (en) * 2002-03-11 2011-02-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparins
US7794965B2 (en) 2002-03-13 2010-09-14 Signum Biosciences, Inc. Method of identifying modulators of PP2A methylase
JP3833129B2 (ja) * 2002-03-19 2006-10-11 株式会社Ａｄｅｋａ 濃縮牛乳状組成物
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
KR20050088243A (ko) 2002-12-30 2005-09-02 넥타르 테라퓨틱스 프리필름화 분무기
US7399496B2 (en) * 2003-02-07 2008-07-15 Glanbia Nutritionals (Ireland) Limited Hydrolyzed whey protein compositions
PT1897548E (pt) 2003-02-28 2013-11-19 Univ Johns Hopkins Regulação de células t
US8071645B2 (en) 2003-06-12 2011-12-06 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
EP1656555B1 (en) 2003-08-20 2012-03-21 Alere San Diego, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US7355593B2 (en) * 2004-01-02 2008-04-08 Smart Technologies, Inc. Pointer tracking across multiple overlapping coordinate input sub-regions defining a generally contiguous input region
US20050163887A1 (en) * 2004-01-23 2005-07-28 Land O' Lakes, Inc. Method of producing heat stable whey protein and products made therefrom
US20070172474A1 (en) * 2004-04-02 2007-07-26 University Of Tennessee Research Foundiation Dairy components effective for fat loss
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
EP1786428B1 (en) 2004-08-17 2012-05-16 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
JP2008511678A (ja) 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
WO2006034454A1 (en) * 2004-09-23 2006-03-30 The Trustees Of The University Of Princeton Bcl-2 family member and bh-3 only proteins for use in development of peptidomimetics
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
NZ537456A (en) * 2004-12-24 2007-10-26 Fonterra Co Operative Group Whey products and a process for preparing a modified whey protein concentrate
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
AU2006216450C1 (en) 2005-02-25 2013-01-10 Medivir Ab Dimeric IAP inhibitors
AU2006235407B2 (en) * 2005-04-11 2011-02-24 University Of Tennessee Research Foundation Stable dairy components effective for fat loss
WO2007002528A1 (en) * 2005-06-23 2007-01-04 Yale University Anti-aging micrornas
WO2007011905A2 (en) 2005-07-19 2007-01-25 The University Of Tennessee Research Foundation Lpa2 receptor agonist inhibitors of cftr
BRPI0615962A2 (pt) 2005-07-27 2011-05-31 Univ Florida uso de um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lisossomal, um inibidor do trasporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador da resposta a choque térmico, um inibidor de glicosidade, e um inibidor de histona deacetilase, uso de 11-cis-retinal ou 9-cis-retinal e um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lissosomal, um inibidor do transporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador de resposta a choque térmico, um inibidor de glicosidase, e um inibidor de histona deacetilase, método para aumentar a quantidade de um conformação bioquimicamente funcional de uma proteìna em uma célula, composição farmacêutica para o tratamento de um pcd ocular, composição farmacêutica para o tratamento de retinite pigmentosa, kit para o tratamento de um pcd ocular, kit para o tratamento de retinite pigmentosa, método para a identificação de um composto útil para o tratamento de um indivìduo que tem um pcd ocular, método para a identificação de um composto útil para o tratamento de um indivìduo que tem retinite pigmentosa, uso de um inibidor proteassomal ou um inibidor de autofagia e método para a produção de uma proteìna recombinante em uma conformação bioquimicamente funcional
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
AU2006279929A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
US20080280834A1 (en) * 2005-12-01 2008-11-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
BRPI0715195A2 (pt) * 2006-07-24 2013-06-11 Tetralogic Pharm Corp composto, mÉtodos para induzir e para estimular a apoptose em uma cÉlula, para intensificar a apoptose de cÉlulas patogÊnicas in vivo em um indivÍduo, e para tratar uma doenÇa, e, composiÇço farmacÊutica
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US8143426B2 (en) * 2006-07-24 2012-03-27 Tetralogic Pharmaceuticals Corporation IAP inhibitors
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
WO2008060791A2 (en) * 2006-10-13 2008-05-22 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
EP2099906B1 (en) 2007-01-05 2014-03-12 Massachusetts Institute of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
JP2010515464A (ja) * 2007-01-11 2010-05-13 イエール・ユニバーシテイ Ｈｉｖ細胞表面受容体の標的化不活性化のための組成物および方法
US20100119474A1 (en) * 2007-03-06 2010-05-13 Cornell University Chronic obstructive pulmonary disease susceptibility and related compositions and methods
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
AU2008262252B2 (en) 2007-06-08 2013-09-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
JP2009000091A (ja) * 2007-06-25 2009-01-08 Sanei Gen Ffi Inc 抱気性乳清タンパク質の調製方法及び該方法によって調製される食品
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
WO2009108745A1 (en) * 2008-02-26 2009-09-03 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
EP2257626A2 (en) * 2008-03-01 2010-12-08 Abraxis BioScience, LLC Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
CA2723716A1 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by mirna
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
EP2328412A4 (en) 2008-09-17 2012-03-14 Tetralogic Pharm Corp IPA INHIBITORS
WO2010033958A1 (en) * 2008-09-22 2010-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear factor kappa b pathway inhibitor composition and use of same
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
EP2421899B1 (en) 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-human ror1 antibodies
EP2432466B1 (en) 2009-04-30 2018-03-28 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Schweinfurthins and uses thereof
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
IN2012DN00352A (ja) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011011797A2 (en) 2009-07-24 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Cytokine compositions and methods of use thereof
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
CN102791742B (zh) * 2010-01-19 2014-12-24 动量制药公司 评价肝素制剂
WO2011133802A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
CA2818992C (en) 2010-12-01 2021-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
WO2012106586A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
WO2012106591A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9296818B2 (en) 2011-03-14 2016-03-29 Marene Inga-Britt Landstrom Cleavage inhibitors of transforming growth factor beta type I receptor and uses thereof in cancer therapy
US9266960B2 (en) 2011-04-08 2016-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
CN103796683A (zh) 2011-04-21 2014-05-14 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物
US9133082B2 (en) 2011-06-14 2015-09-15 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
JP2014523914A (ja) 2011-07-18 2014-09-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作された微生物標的化分子およびその使用
CA2844197A1 (en) 2011-08-03 2013-02-07 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolina Healthcare System Treatment of fibrosis using microrna-19b
AU2012325341B2 (en) 2011-10-19 2017-01-05 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗ｃｄ２２キメラ抗原受容体
CA2862807A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP2785178B1 (en) 2011-12-01 2019-05-01 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA3209571A1 (en) 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
CA2871490C (en) 2012-04-27 2022-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing
US9790278B2 (en) 2012-05-07 2017-10-17 The Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
JP5879437B2 (ja) * 2012-06-15 2016-03-08 森永乳業株式会社 改質ホエイ組成物の製造方法、およびカルシウム増強改質ホエイ組成物の製造方法
US9119858B2 (en) 2012-08-21 2015-09-01 Genesys Research Institute, Inc. Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
RU2658485C2 (ru) 2012-10-24 2018-06-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы м971
EP2730170B1 (de) 2012-11-13 2016-02-10 DMK Deutsches Milchkontor GmbH Allergenfreie Nahrungsmittelzusammensetzungen
US9872851B2 (en) 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
US9750718B2 (en) 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
JP6457999B2 (ja) 2013-03-14 2019-01-23 ザ チルドレンズ メディカル センター コーポレーション 処置に関してがんの対象を識別するためのｃｄ３６の使用
EP2970411B1 (en) 2013-03-15 2018-05-09 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
EP2981280A2 (en) 2013-04-04 2016-02-10 IEO - Istituto Europeo di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
EA036275B1 (ru) 2013-06-25 2020-10-21 Дзе Уолтер Энд Элиза Хол Инститьют Оф Медикал Рисерч Способ лечения внутриклеточной инфекции
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
EP3060238A4 (en) 2013-10-21 2017-06-07 Salk Institute for Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
CA2932424C (en) 2013-12-06 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
CN105828830A (zh) 2013-12-16 2016-08-03 雀巢产品技术援助有限公司 最新鉴定出的用于诱导幼年哺乳动物口服耐受性的肽
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
JP6727129B2 (ja) 2014-03-26 2020-07-22 ザ チルドレンズ メディカル センター コーポレーション 環状プロサポシンペプチドおよびその使用
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US10272019B2 (en) 2014-05-09 2019-04-30 Yale University Topical formulation of hyperbranched polyglycerol-coated particles thereof
CA2961609C (en) 2014-09-17 2023-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 antibodies (b7h3)
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
EP3270937A4 (en) 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
KR20180033499A (ko) 2015-06-05 2018-04-03 아이바이오, 인크. 섬유증을 치료하는데 사용하기 위한 엔도스타틴 단편 및 변이체
EP3109257B1 (en) 2015-06-26 2021-01-06 Prindex S.r.l. Diagnosis and therapy of multiple sclerosis
EP3313519B1 (en) 2015-06-29 2023-05-31 Children's Medical Center Corporation Jak-stat inhibitors for the treatment of congenital myopathies
EP3331549B1 (en) 2015-08-06 2020-12-23 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
US10806170B2 (en) 2015-12-18 2020-10-20 Societe Des Produits Nestle S.A. Heat sterilized high protein compositions comprising whey protein and at least one component selected from (i) a saccharide, (ii) a phosphate and (iii) a citrate
CA3011815A1 (en) 2016-01-20 2017-07-27 The Scripps Research Institute Ror1 antibody compositions and related methods
US11078273B2 (en) 2016-01-20 2021-08-03 The Scripps Research Institute ROR2 antibody compositions and related methods
WO2017143061A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
CN109476706A (zh) 2016-02-16 2019-03-15 耶鲁大学 用于促进靶向基因编辑的组合物及其使用方法
MX2018012719A (es) 2016-04-19 2019-05-30 Us Health Ram negativas para tratar la dermatitis atopica.
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
AU2017266686B2 (en) 2016-05-16 2023-03-09 Checkmab S.R.L Markers selectively deregulated in tumor-infiltrating regulatory T cells
WO2017205747A1 (en) 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
WO2018005799A1 (en) 2016-06-29 2018-01-04 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
WO2018005759A1 (en) 2016-07-01 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
CN115380987A (zh) * 2016-07-15 2022-11-25 阿拉食品公司 生产浓缩或干燥的酸可胶凝的乳清蛋白聚集体的方法，以及相关的组合物和食品
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
WO2019189350A1 (ja) * 2018-03-30 2019-10-03 雪印メグミルク株式会社 κ－カゼイングリコマクロペプチドを含む組成物の製造方法
EP3790563A4 (en) 2018-05-11 2022-03-23 Forte Subsidiary, Inc. COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS
CN109045278B (zh) * 2018-07-09 2022-06-21 苏州恒瑞健康科技有限公司 一种稳定的乳蛋白质液态体系及其应用
US11266617B2 (en) 2018-10-16 2022-03-08 Massachusetts Institute Of Technology Beta-hydroxybutyrate encapsulated PLGA nanoparticle compositions
US20210340562A1 (en) 2018-10-19 2021-11-04 Board Of Regents, The University Of Texas System Engineered long interspersed element (line) transposons and methods of use
BR112021009955A2 (pt) 2018-12-19 2021-08-17 Société des Produits Nestlé S.A. Usos de um hidrolisado de proteína parcial do soro de leite, e composição para prevenirou reduzir a perda transepidérmica de água e melhorar a função de barreira da pele
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
CA3127025A1 (en) 2019-01-18 2020-07-23 Janssen Biotech, Inc. Gprc5d chimeric antigen receptors and cells expressing the same
KR20210122275A (ko) 2019-01-30 2021-10-08 얀센 파마슈티카 엔.브이. 분자 아형에 기초하여 전립선암을 치료하는 방법
US20220054494A1 (en) 2019-03-13 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
AU2020271123A1 (en) 2019-04-10 2021-11-25 Elevatebio Technologies, Inc. FLT3-specific chimeric antigen receptors and methods of using the same
SG11202112922WA (en) 2019-05-22 2021-12-30 Massachusetts Inst Technology Circular rna compositions and methods
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
AU2020322221A1 (en) 2019-07-26 2022-03-24 Janssen Biotech, Inc. Anti-hK2 chimeric antigen receptor (CAR)
BR112022001368A2 (pt) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
AU2020334317A1 (en) 2019-08-16 2022-04-07 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
JP2023502652A (ja) 2019-11-18 2023-01-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ７９キメラ抗原受容体、ｃａｒ－ｔ細胞、及びそれらの使用
EP4084623B1 (en) * 2019-12-30 2024-05-01 Arla Foods amba Method of producing dense whey protein nanogels, the resulting whey protein nanogels or nanogel compositions, and use of such whey protein nanogels or nanogel compositions
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
EP4233893A3 (en) 2020-03-13 2023-09-27 Janssen Biotech, Inc. Materials and methods for binding siglec-3/cd33
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
CA3179423A1 (en) 2020-05-19 2021-11-25 Robert Alexander WESSELHOEFT Circular rna compositions and methods
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
CN116615256A (zh) 2020-10-16 2023-08-18 乔治亚大学研究基金会 糖缀合物
JP2024512035A (ja) 2021-03-24 2024-03-18 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ２２及びｃｄ７９ｂを標的とする抗体
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
CN118541346A (zh) 2021-11-08 2024-08-23 奥纳治疗公司 用于递送环状多核苷酸的脂质纳米颗粒组合物
WO2023231959A2 (en) 2022-05-30 2023-12-07 Shanghai Circode Biomed Co., Ltd Synthetic circular rna compositions and methods of use thereof
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024129982A2 (en) 2022-12-15 2024-06-20 Orna Therapeutics, Inc. Circular rna compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1085380A (en) * 1913-03-28 1914-01-27 Adam Thomas Bell Whey emulsion.
US1609617A (en) * 1926-06-15 1926-12-07 William O Frohring Method of increasing the coagulating point of milk
US1954769A (en) * 1930-12-08 1934-04-10 M & R Dietetic Lab Inc Treating milk products
US2570231A (en) * 1946-01-04 1951-10-09 Hansen Francis Frederick Condensed milk composition and its preparation
US2555514A (en) * 1947-01-20 1951-06-05 Golden State Company Ltd Whey product derived from milk and process of producing same
FR1523106A (fr) * 1962-06-15 1968-05-03 Afico Sa Lait en poudre pour nourrissons et son procédé de fabrication
DE1692294A1 (de) * 1966-09-14 1971-07-29 United Brands Co Verfahren zur Stabilisierung kondensierter Milch
US3791283A (en) * 1970-08-28 1974-02-12 Gen Foods Corp Method for producing heat and acid stable whey protein material
DE2138277C2 (de) * 1971-07-30 1982-09-16 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Verfahren zur Herstellung eines Molkeeiweißkonzentrates
CH556143A (fr) * 1972-09-11 1974-11-29 Nestle Sa Procede de preparation d'une fraction soluble des proteines du petit lait.
NL7603369A (en) * 1976-03-31 1977-10-04 Stichting Bedrijven Van Het Selective removal of inorganic ions from aq. protein concentrates - by ultrafiltration and diafiltration at controlled pH
FR2391653A1 (fr) * 1977-05-23 1978-12-22 Nestle Sa Soc Ass Tech Prod Procede de traitement du lactoserum
NL181326C (nl) * 1979-11-20 1987-08-03 Stichting Bedrijven Van Het Werkwijze voor de bereiding van voedingsmiddelen waarin een in water oplosbare gedenatureerde wei-eiwitsamenstelling wordt opgenomen alsmede werkwijze ter bereiding van oplosbare gedenatureerde wei-eiwitsamenstellingen.
JPS603814B2 (ja) * 1981-10-02 1985-01-30 協和醗酵工業株式会社 改質ホエ−蛋白貿の製造法
US4460615A (en) * 1981-10-02 1984-07-17 Kyowa Hakko Kogyo Kabushiki Kaisha Process for improving the quality of whey protein
US4497836A (en) * 1982-08-06 1985-02-05 Dairy Technology Ltd. Modified whey product and process including ultrafiltration and demineralization

Also Published As

Publication number Publication date
MX167579B (es) 1993-03-30
GB2139630A (en) 1984-11-14
US4748034A (en) 1988-05-31
NZ208086A (en) 1986-06-11
ES8506983A1 (es) 1985-09-01
SG35687G (en) 1988-09-23
ATE24658T1 (de) 1987-01-15
AU564405B2 (en) 1987-08-13
GB2139630B (en) 1987-01-07
JPS59216544A (ja) 1984-12-06
AU2755184A (en) 1984-11-15
MY100729A (en) 1991-01-31
ZA843213B (en) 1984-12-24
ES532469A0 (es) 1985-09-01
GB8411196D0 (en) 1984-06-06
EP0126290A1 (fr) 1984-11-28
EP0126290B1 (fr) 1987-01-07
EP0126290B2 (fr) 1994-03-30
HK73787A (en) 1987-10-16
DE3461886D1 (en) 1987-02-12
CA1200416A (en) 1986-02-11
DK235584D0 (da) 1984-05-11
JPS646739B2 (ja) 1989-02-06

Similar Documents

Publication Publication Date Title
GB2139630B (en) Food process
PT84820B (pt) Processo para a preparacao de bebidas de sumo de frutos e de concentrados de sumo com suplemento nutritivo de calcio
AU587365B2 (en) Pasteurized human fibrinogen (HF), a process for its preparation and its use
PH23256A (en) A process for the preparation of quinolone carboxylic acid derivatives
ES2027744T3 (es) Procedimiento de preparacion de un producto lactoserico de alergenicidad reducida.
EP0279619A3 (en) Production of proteins in active forms
DE3464849D1 (en) Stable, aqueous, acidic solution of cis-platinum, suitable for injection
CA2040496A1 (en) Method for preparing an aqueous food supplement for cattle and thus prepared food supplement
AU571818B2 (en) Reduced phosphate & calcium milk for infants
IE801358L (en) Gelling of whey proteins.
AU558927B2 (en) Gelled gelatin food product
ES8401308A1 (es) "un procedimiento para inhibir la perdida de humedad de camarones crudos al congelarlos o cocerlos".
AU1207688A (en) Process for sterilising an aqueous suspension of an insoluble salt in water
ES450053A1 (es) Un procedimiento para elaborar un producto de proteina tex- turizada.
JPS5685250A (en) Preparation of novel protein material
ES8405359A1 (es) Procedimiento para preparar derivados farmaceuticamente aceptables de 2-dietilamino-metiletil-cis-1-hidroxi-(biciclohexil)-2-carboxilato.
JPS5685251A (en) Preparation of novel protein material
GB2255705A (en) Gelling system
HUT38803A (en) Process for producing enzymatically modified egg white